International Journal of Multidisciplinary Research and Growth Evaluation.

Leveraging Artificial Intelligence for Real-Time Cleaning Validation: A Risk-Based Lifecycle Approach to Pharma 4.0

Birju Patel [1*], Nageswara Pacha [2], Jayminkumar Patel [3]
[1] Validation Engineering, Anika Therapeutics, Bedford, MA, USA
[2] Validation Specialist, TechData Service Company LLC, King of Prussia, PA, USA
[3] Analytical R and D, Amneal Pharmaceuticals, Piscataway, NJ, USA

* Corresponding Author: **Birju Patel**

Article Info

ISSN (Online): 2582-7138
Impact Factor (RSIF): 8.04
Volume: 07
Issue: 02
March-April 2026
Received: 20-01-2026
Accepted: 22-02-2026
Published: 24-03-2026
Page No: 474-484

Abstract

Background: Cleaning validation remains a critical quality assurance function in pharmaceutical manufacturing, ensuring the prevention of cross-contamination and safeguarding patient safety. Traditional approaches rely on manual swab sampling, extended laboratory turnaround times for High-Performance Liquid Chromatography (HPLC) or Total Organic Carbon (TOC) analysis, and rigid worst-case scenario protocols. These methodologies, while effective, create operational bottlenecks that limit equipment utilization and introduce opportunities for human error in documentation.

Objective: This review examines how artificial intelligence (AI) and machine learning (ML) technologies can transform cleaning validation from a retrospective, compliance-driven activity into a continuous, predictive quality assurance paradigm aligned with Pharma 4.0 principles and lifecycle-based regulatory frameworks.

Methods: A comprehensive literature review was conducted examining AI-driven tools including computer vision systems, Near-Infrared (NIR) spectroscopy with chemometric analysis, predictive modeling algorithms, and Natural Language Processing (NLP) applications. Regulatory guidance documents from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and International Council for Harmonisation (ICH) were analyzed for alignment with AI implementation strategies.

Key Findings: Integration of AI technologies in cleaning validation demonstrates potential for significant operational improvements, with studies indicating cleaning cycle time reductions of 20 to 40 percent through process optimization. AI-enhanced Process Analytical Technology (PAT) enables real-time residue monitoring, while computer vision systems provide automated visual inspection capabilities that exceed human performance in consistency and throughput. Data integrity requirements under ALCOA+ principles can be strengthened through automated audit trails and electronic signature systems inherent to AI platforms.

Conclusions: AI-enabled cleaning validation represents a paradigm shift from reactive verification to predictive assurance. Successful implementation requires careful consideration of regulatory compliance, particularly regarding the validation of AI systems themselves, Explainable AI (XAI) requirements, and human-in-the-loop oversight. Organizations that adopt these technologies position themselves for enhanced operational efficiency while maintaining the highest quality standards aligned with ICH Q9 and Q10 lifecycle principles.

DOI: https://doi.org/10.54660/.IJMRGE.2026.7.2.474-484

Keywords: Artificial Intelligence, Machine Learning, Cleaning Validation, Pharma 4.0, Process Analytical Technology

1. Introduction

1.1. The Criticality of Cleaning Validation

Cleaning validation constitutes one of the most fundamental pillars of pharmaceutical quality assurance. The systematic verification that manufacturing equipment is free from product residues, cleaning agents, and microbial contamination serves as the primary safeguard against cross-contamination, which represents a significant risk to patient safety [1]. Regulatory authorities worldwide recognize that inadequate cleaning procedures can lead to contamination of subsequent product batches, potentially

resulting in therapeutic failures, adverse reactions, or in extreme cases, patient fatalities [2].

The pharmaceutical industry's cleaning validation paradigm has evolved considerably since its formalization in the 1990s. Initial approaches focused primarily on demonstrating equipment cleanliness through analytical testing, typically requiring three consecutive successful cleaning cycles to establish a validated state [3]. This "three-batch" approach, while providing a statistical basis for confidence, established an inherently retrospective and rigid framework that continues to dominate industry practice despite advances in process understanding and analytical capabilities.

The prevention of cross-contamination extends beyond active pharmaceutical ingredients (APIs) to encompass cleaning agent residues, microbial contamination, and degradation products. Modern toxicology-based approaches, incorporating concepts such as Permitted Daily Exposure (PDE) derived from health-based exposure limits, have refined acceptance criteria calculation methodologies [4]. However, the fundamental mechanics of validation execution, relying on manual sampling, offline analysis, and paper-based documentation, have remained largely unchanged in many facilities.

1.2. The Current State: Traditional Methodologies and Their Limitations

Contemporary cleaning validation practices predominantly employ two analytical methodologies: High-Performance Liquid Chromatography (HPLC) for specific analyte detection and Total Organic Carbon (TOC) analysis for non-specific organic residue quantification [5]. Swab sampling of defined surface areas and rinse sampling of final wash solutions constitute the primary sample collection techniques, each with inherent advantages and limitations regarding accessibility, recovery efficiency, and surface coverage.

The workflow associated with traditional cleaning validation creates significant operational constraints. Following equipment cleaning, trained personnel must collect swab samples from predetermined locations, often requiring disassembly of equipment components to access internal surfaces. Samples are then transported to quality control laboratories where analytical testing may require several hours to days for completion, depending on method complexity and laboratory workload [6]. Only upon receipt of acceptable results can equipment be released for subsequent production campaigns.

This sequential, time-dependent process creates what industry practitioners term the "validation bottleneck." Manufacturing equipment may sit idle awaiting analytical results, reducing Overall Equipment Effectiveness (OEE) and increasing production costs. The pressure to minimize downtime can inadvertently create incentives for procedural shortcuts or documentation deficiencies, particularly in high-volume manufacturing environments operating multiple shifts.

Human error represents a persistent vulnerability in traditional cleaning validation systems. Manual transcription of results, subjective interpretation of visual cleanliness, inconsistent swabbing techniques, and documentation omissions have been cited repeatedly in regulatory observations [7]. The FDA's analysis of warning letters consistently identifies data integrity violations, many stemming from manual documentation practices, as among the most common compliance deficiencies in pharmaceutical manufacturing.

1.3. Problem Statement: The Imperative for Transformation

The pharmaceutical industry faces mounting pressures that expose the inadequacies of traditional cleaning validation approaches. Product portfolios have expanded dramatically, with many facilities manufacturing dozens or even hundreds of products on shared equipment. The introduction of highly potent active pharmaceutical ingredients (HPAPIs), biologics, and personalized medicines has increased the complexity and stakes associated with cross-contamination prevention [8]. Meanwhile, market demands for accelerated product availability and cost-competitive pricing intensify pressure on manufacturing efficiency.

The traditional cleaning validation paradigm struggles to accommodate this complexity. Worst-case product grouping strategies, while scientifically sound, become unwieldy when product portfolios expand. Revalidation requirements following process or equipment changes create administrative burdens that can slow operational responsiveness. Perhaps most critically, the retrospective nature of traditional validation provides assurance of past performance without predictive capability for ongoing operations.

Data integrity concerns have elevated to the forefront of regulatory attention. Regulatory agencies globally have issued guidance emphasizing the ALCOA+ principles: data must be Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available [9]. Traditional paper-based systems, while capable of compliance, require substantial procedural controls and are inherently more susceptible to manipulation than properly designed electronic systems.

1.4. The Role of Artificial Intelligence: Enabling the Paradigm Shift

Artificial intelligence and machine learning technologies offer transformative potential for addressing these challenges. AI systems can process vast quantities of data in real-time, identify patterns invisible to human analysts, and provide predictive insights that enable proactive rather than reactive quality management. When integrated with Process Analytical Technology (PAT) sensors, AI creates the foundation for continuous process verification extending beyond traditional validation boundaries.

The alignment between AI capabilities and contemporary regulatory philosophy is particularly noteworthy. The FDA's Quality by Design (QbD) initiative emphasizes building quality into products and processes through enhanced understanding rather than relying solely on end-product testing [10]. The ICH Q8, Q9, and Q10 guidelines establish a framework for pharmaceutical development, quality risk management, and pharmaceutical quality systems that emphasizes science-based and risk-based approaches throughout the product lifecycle [11]. AI technologies provide the analytical power necessary to operationalize these principles in cleaning validation.

The emergence of Pharma 4.0, the pharmaceutical industry's adaptation of Industry 4.0 concepts, positions AI

as a central enabler of digital transformation in manufacturing [12]. Connected sensors, integrated data systems, and intelligent analytics create "smart factory" environments where processes are continuously monitored, analyzed, and optimized. Within this framework, cleaning validation evolves from a discrete, periodic activity to an embedded component of ongoing process control.

This review examines the current state and future potential of AI technologies in pharmaceutical cleaning validation. We explore the theoretical basis and practical applications of machine learning for predictive modeling, computer vision for automated inspection, PAT integration for real-time monitoring, and natural language processing for documentation review. Regulatory considerations, implementation challenges, and organizational factors are addressed to provide a comprehensive perspective for industry practitioners considering AI adoption in their cleaning validation programs.

2. Theoretical Framework: AI Technologies in Cleaning Validation

2.1. Machine Learning for Predictive Modeling

Machine learning (ML), a subset of artificial intelligence, encompasses algorithms that improve their performance through exposure to data without explicit programming for each specific task [13]. In the context of cleaning validation, ML algorithms can analyze historical cleaning data to identify factors influencing cleaning effectiveness and predict outcomes for future cleaning cycles.

2.1.1. Supervised Learning Approaches

Supervised learning algorithms train on labeled datasets where both input features and desired outputs are known. For cleaning validation applications, historical data might include input variables such as soil type (product characteristics), soil load (batch size), equipment geometry, cleaning agent concentration, temperature, flow rate, and cleaning time. Output variables would include residue levels measured by swab or rinse analysis, visual inspection results, and microbial counts.

Random Forest algorithms, which construct multiple decision trees and aggregate their predictions, have demonstrated utility in pharmaceutical process optimization due to their ability to handle nonlinear relationships and interactions between variables [14]. Support Vector Machines (SVMs) provide robust classification capabilities, potentially distinguishing between "clean" and "not clean" states based on multivariate input data. Neural networks, particularly deep learning architectures, offer the greatest flexibility for modeling complex relationships but require larger training datasets and present interpretability challenges.

The practical application involves developing models that predict residue levels based on process parameters. A facility could input the characteristics of an upcoming cleaning cycle (product just manufactured, batch size, equipment train, planned cleaning parameters) and receive a predicted residue level with associated confidence interval. If the prediction indicates high probability of exceeding acceptance limits, parameters could be adjusted proactively rather than discovering failure after cleaning completion.

2.1.2. Unsupervised Learning for Anomaly Detection

Unsupervised learning algorithms identify patterns in data without predefined labels. Clustering algorithms such as K-means or hierarchical clustering can segment cleaning cycles into groups based on similarity, potentially revealing unexpected patterns or outliers. Autoencoders, neural network architectures trained to reconstruct their inputs, can detect anomalies by identifying cycles that deviate significantly from learned normal patterns.

Anomaly detection offers particular value for identifying "drifting" cleaning performance before it results in validation failures. Gradual changes in cleaning effectiveness, potentially due to equipment wear, cleaning agent degradation, or procedural drift, may not be apparent from individual data points but become visible when analyzed through ML pattern recognition [15]. Early identification enables preventive intervention, maintaining validated status while avoiding the operational and regulatory consequences of cleaning failures.

2.1.3. Reinforcement Learning for Process Optimization

Reinforcement learning algorithms learn optimal behaviors through interaction with an environment, receiving feedback in the form of rewards or penalties. While less commonly applied in pharmaceutical manufacturing due to regulatory constraints on experimentation, RL concepts inform adaptive control strategies where cleaning parameters are adjusted based on real-time feedback.

A reinforcement learning approach might optimize cleaning cycle duration, seeking the minimum effective cleaning time that reliably achieves acceptance criteria. The algorithm would balance the reward of reduced cleaning time against the penalty of cleaning failures, learning through simulated or controlled experimentation to identify optimal parameters for various product and equipment combinations.

2.2. Computer Vision and Image Analysis

Computer vision systems employ cameras and image processing algorithms to extract information from visual data. In pharmaceutical manufacturing, computer vision has been applied extensively to visual inspection of products and packaging, with established regulatory acceptance [16]. Extension to cleaning verification represents a natural evolution of these capabilities.

2.2.1. Deep Learning for Visual Inspection

Convolutional Neural Networks (CNNs) have revolutionized image analysis by automatically learning hierarchical feature representations from raw pixel data [17]. Rather than requiring explicit programming of visual features (edges, textures, shapes), CNNs learn relevant features during training on annotated image datasets. This capability has enabled performance exceeding human inspectors for many visual inspection tasks.

For cleaning verification, CNN-based systems can be trained to identify visible residues, staining, or other indicators of inadequate cleaning on equipment surfaces. High-resolution cameras positioned to view equipment interiors, potentially including hard-to-access areas such as pipe joints, valve seats, or heat exchanger surfaces,

provide images for analysis. The CNN model, trained on images labeled as "clean" or containing various residue types, classifies new images and flags areas of concern.

Object detection architectures such as YOLO (You Only Look Once) and Faster R-CNN enable localization of specific features within images [18]. Rather than simply classifying an entire image as clean or contaminated, these systems can identify and locate specific residue deposits, providing actionable information for targeted re-cleaning if necessary.

2.2.2. Hyperspectral and Multispectral Imaging

Beyond conventional RGB imaging, hyperspectral cameras capture data across numerous narrow wavelength bands throughout the electromagnetic spectrum. This spectral information enables chemical identification in addition to spatial visualization, effectively combining imaging with spectroscopic analysis [19]. Residues invisible to conventional cameras may present distinctive spectral signatures detectable through hyperspectral analysis.

The integration of hyperspectral imaging with AI analysis creates powerful capabilities for cleaning verification. Neural networks trained on hyperspectral data can simultaneously identify residue presence, estimate concentration, and in some cases identify chemical composition. This multimodal analysis provides richer information than either visual inspection or point-based chemical analysis alone.

2.2.3. Implementation Considerations

Practical implementation of computer vision for cleaning verification requires careful consideration of imaging conditions. Lighting must be consistent and sufficient to illuminate target surfaces without creating reflections or shadows that could confound analysis. Camera positioning must ensure coverage of relevant surfaces while accommodating the geometry of pharmaceutical equipment. Image resolution must be sufficient to detect residues at relevant acceptance limits.

Validation of computer vision systems presents unique challenges. Traditional validation approaches verify that systems produce correct outputs for known inputs, but the diversity of potential visual presentations complicates comprehensive testing. Robustness to variations in lighting, surface conditions, and residue appearance must be demonstrated. Reference standards for visual detection limits must be established and periodically verified.

2.3. Process Analytical Technology Integration

Process Analytical Technology, as defined by the FDA, encompasses systems for analysis and control of manufacturing processes based on timely measurements of critical quality and performance attributes [20]. PAT represents a fundamental shift from end-product testing to in-process monitoring, enabling real-time release and continuous process verification.

2.3.1. Spectroscopic Methods for Real-Time Monitoring

Near-Infrared (NIR) spectroscopy has emerged as a particularly valuable PAT tool due to its non-destructive nature, rapid analysis time, and sensitivity to organic compounds [21]. NIR spectra contain information about molecular composition through absorption bands corresponding to overtones and combinations of fundamental molecular vibrations. Chemometric analysis, employing multivariate statistical methods, extracts quantitative information from complex spectra.

For cleaning applications, NIR probes can be integrated into cleaning-in-place (CIP) systems to monitor rinse solutions continuously. The spectral signature of rinse water changes as product residues are removed, with clean rinse water presenting a distinctive spectrum [22]. Chemometric models, typically employing Partial Least Squares (PLS) regression, correlate spectral features with residue concentration, enabling real-time quantification.

UV-Visible spectroscopy provides complementary capabilities, particularly for aromatic compounds and other chromophores. Raman spectroscopy, while less commonly applied in cleaning applications, offers high chemical specificity and the ability to analyze aqueous solutions without interference from water absorption. The selection of spectroscopic technique depends on the chemical properties of target analytes and the specific application requirements.

2.3.2. AI-Enhanced Spectral Interpretation

Traditional chemometric analysis employs linear models relating spectral features to analyte concentration. While effective for well-characterized systems, these models may struggle with complex, multicomponent residue mixtures or non-linear relationships. Machine learning algorithms offer enhanced capabilities for spectral interpretation.

Deep learning approaches, particularly architectures incorporating convolutional layers for feature extraction from spectral data, have demonstrated superior performance for complex spectroscopic analysis tasks [23]. Neural networks can learn to recognize patterns in spectra that correlate with cleaning endpoint or residue presence without requiring explicit specification of relevant wavelengths or spectral features.

Transfer learning techniques enable application of models trained on large spectroscopic databases to specific cleaning validation applications with limited site-specific training data. Pre-trained models learn general features of spectral data that can be fine-tuned for particular products and equipment, reducing the data requirements for model development.

2.3.3. Multi-Sensor Data Fusion

Modern CIP systems may incorporate multiple sensors measuring complementary parameters: conductivity (indicating dissolved ionic species), pH, temperature, turbidity, and spectroscopic signals. AI systems can integrate data from multiple sensors to provide more robust and comprehensive cleaning assessment than any single measurement.

Data fusion algorithms combine information from different sensors, weighting their contributions based on relevance and reliability for specific cleaning scenarios [24]. A machine learning model might learn that conductivity is highly informative during initial rinsing (detecting removal of cleaning agents) while spectroscopic signals become more relevant in later stages (detecting trace product residues). This intelligent integration maximizes the information extracted from the

sensor array.

2.4. Natural Language Processing for Documentation Review

Natural Language Processing (NLP) encompasses AI techniques for understanding and generating human language. While less directly connected to physical cleaning processes, NLP offers significant potential for improving documentation review and compliance monitoring within cleaning validation programs.

2.4.1. Automated Review of Batch Records and Logs

Pharmaceutical manufacturing generates substantial documentation, including batch production records, cleaning logs, deviation reports, and corrective action records. Manual review of these documents for completeness, consistency, and compliance requires significant quality assurance resources and is subject to reviewer fatigue and oversight.

NLP algorithms can parse unstructured text in manufacturing documents, extracting key information and flagging potential issues for human review [25]. Named entity recognition identifies references to equipment, products, personnel, and dates. Sentiment analysis and anomaly detection algorithms can identify unusual language patterns that may indicate problems or deviations from expected procedures.

2.4.2. Deviation Detection and Trending

Cleaning-related deviations and investigations generate narrative documentation describing failure modes, root causes, and corrective actions. NLP analysis of these documents can identify recurring themes, emerging issues, or systemic problems that might not be apparent from structured data alone.

Topic modeling algorithms such as Latent Dirichlet Allocation (LDA) can discover common themes across deviation reports, potentially revealing patterns such as recurring equipment problems, procedural ambiguities, or training deficiencies. Time-series analysis of deviation narratives can detect emerging issues before they become widespread.

2.4.3. Regulatory Intelligence

NLP techniques can also support regulatory monitoring, automatically scanning new guidance documents, warning letters, and inspection observations for content relevant to cleaning validation. This intelligence helps organizations stay current with regulatory expectations and learn from enforcement actions at other facilities.

3. Case Studies and Applications

3.1. Cycle Time Optimization Through Predictive Modeling

The optimization of cleaning cycle duration represents one of the most immediately impactful applications of AI in cleaning validation. Traditional cleaning procedures often employ substantial safety margins, with cycle times extended well beyond the minimum necessary to ensure consistent achievement of acceptance criteria. While this conservative approach ensures compliance, it imposes unnecessary costs in terms of equipment downtime, utility consumption (water, energy, cleaning agents), and environmental impact.

Studies examining cleaning process optimization have demonstrated that strategic interventions can reduce cleaning cycle times by 20 to 40 percent depending on baseline practices and the specific optimization approaches employed [26]. In one documented example, a syrup manufacturing line utilized a standard CIP protocol requiring 120 minutes per cycle. Analysis identified opportunities in prolonged rinse durations and idle waiting periods between stages. Implementation of rinse validation data, demonstrating that shorter rinse times achieved equivalent cleanliness, combined with automated valve sequencing to eliminate manual delays, reduced the total cycle time to 85 minutes, enabling an additional production batch per day.

AI predictive models enable more sophisticated optimization by determining the minimum effective cleaning time for specific product and equipment combinations. Historical data analysis can reveal that certain products require longer cleaning times while others can be cleaned effectively in substantially shorter periods [27]. Rather than applying a single worst-case cycle time to all products, AI-enabled systems can recommend product-specific parameters that maintain quality while minimizing operational impact.

The development of such predictive models requires comprehensive historical data encompassing product characteristics (solubility, adhesion properties, concentration), process parameters (cleaning agent, temperature, flow rate, time), equipment factors (material of construction, surface finish, geometry), and outcomes (residue levels, visual inspection results). Machine learning algorithms identify the relationships between these variables, generating models that predict cleaning outcomes for new combinations.

3.2. Anomaly Detection and Predictive Quality

Beyond optimization of individual cleaning cycles, AI enables monitoring of cleaning process performance over time to detect gradual degradation before it results in failures. Equipment surfaces may become roughened through use, reducing cleanability. Spray devices may become partially occluded, reducing cleaning effectiveness. Procedural drift, where operators gradually deviate from documented procedures, can introduce variability.

Statistical Process Control (SPC) techniques have traditionally been applied to trending of cleaning results, with control charts flagging data points outside expected ranges [28]. While effective for detecting sudden shifts, traditional SPC may miss gradual trends, particularly when normal variation is substantial. Machine learning algorithms can identify subtle patterns in multidimensional data that presage cleaning difficulties.

Anomaly detection models establish baseline patterns from historical data, then flag new observations that deviate significantly from these patterns. The deviation may not be apparent in any single measurement but becomes visible when considering the full constellation of process parameters and outcomes. Early warning enables investigation and corrective action before cleaning failures occur, maintaining validated status while avoiding the operational disruption and regulatory implications of cleaning deviations.

3.3. Risk-Based Sampling Strategy Development

Traditional cleaning validation sampling strategies often specify numerous sampling locations to ensure comprehensive coverage of equipment surfaces. While thorough, this approach imposes substantial sampling and analytical burden, particularly for large or complex equipment trains. Risk-based approaches, advocated by regulatory guidance, concentrate sampling effort on locations most likely to harbor residues.

AI analysis of historical data and equipment characteristics can inform risk-based sampling strategy development [29]. Machine learning models can identify locations consistently associated with higher residue levels, suggesting these as critical sampling points. Conversely, locations consistently found clean may be candidates for reduced sampling frequency in ongoing verification.

Computational Fluid Dynamics (CFD) simulations model cleaning solution flow patterns within equipment, identifying areas of low flow velocity or inadequate spray coverage, termed "dead legs" [30]. AI integration with CFD enables optimization of both cleaning procedures (adjusting flows to improve coverage of problem areas) and sampling strategies (targeting identified risk locations).

The transition from comprehensive to risk-based sampling requires scientific justification documented in validation protocols. AI analysis provides the quantitative basis for this justification, demonstrating through data analysis that the proposed reduced sampling strategy maintains equivalent assurance of detecting inadequate cleaning.

4. Regulatory Landscape and Compliance Considerations

4.1. Data Integrity and ALCOA+ Principles

Data integrity has emerged as a paramount regulatory concern, with agencies worldwide issuing guidance and enforcement actions addressing deficiencies in data management practices. The FDA's guidance document on data integrity and compliance with current Good Manufacturing Practice (cGMP) emphasizes that data integrity is fundamental to GMP compliance, affecting all aspects of pharmaceutical manufacturing including cleaning validation [31].

The ALCOA+ framework provides the conceptual basis for data integrity requirements. Data must be Attributable to the person who generated it, Legible and permanent, recorded Contemporaneously at the time of the activity, preserved as the Original record (or a certified true copy), and Accurate [32]. The expanded ALCOA+ principles add that data must be Complete, Consistent, Enduring (durable), and Available when needed.

AI systems, when properly designed and validated, can strengthen data integrity through several mechanisms. Automated data capture eliminates manual transcription, a common source of errors and a vulnerability for manipulation. Secure database architectures with access controls and audit trails provide the attribution and contemporaneous recording required by ALCOA+ principles. Backup systems and data archiving address endurance and availability requirements.

The FDA's 21 CFR Part 11 regulation establishes requirements for electronic records and electronic signatures in regulated activities [33]. Systems used to generate, modify, maintain, archive, retrieve, or transmit records required by predicate rules must meet requirements for system validation, audit trails, access controls, and operational system checks. AI systems used in cleaning validation must be designed and validated to comply with these requirements.

4.2. Validation of AI Systems: The "Black Box" Challenge

The validation of AI systems presents unique challenges distinct from traditional software validation. Traditional software validation verifies that the system produces expected outputs for defined inputs, essentially confirming that programmed logic executes correctly. AI systems, particularly those employing deep learning, develop their logic through training rather than explicit programming, creating models whose internal workings may not be readily interpretable, the so-called "black box" problem [34].

Regulatory agencies have recognized this challenge and are developing frameworks for AI validation. The FDA's January 2025 draft guidance on the use of artificial intelligence to support regulatory decision-making for drug and biological products establishes a risk-based credibility assessment framework [35]. This framework emphasizes that model credibility must be established for the specific context of use, considering factors including data quality, model development rigor, and ongoing performance monitoring.

The concept of "progressive validation" acknowledges the evolutionary nature of AI models. Unlike traditional software that remains static between version updates, AI models may improve over time through exposure to additional data or retraining. Regulatory frameworks must accommodate this characteristic while ensuring that model changes are appropriately controlled and documented [36].

4.3. Explainable AI Requirements

The regulatory emphasis on transparency and understanding has elevated Explainable AI (XAI) from an academic research topic to a practical compliance requirement. XAI encompasses techniques that make AI model decisions interpretable to human users, enabling understanding of why a model produced a particular output [37].

For cleaning validation applications, XAI might involve identifying which input variables most strongly influenced a cleaning outcome prediction, highlighting image regions that triggered a computer vision assessment of inadequate cleanliness, or explaining why an anomaly detection algorithm flagged a particular cleaning cycle. This information supports human review and decision-making, maintains human-in-the-loop oversight, and provides documentation for regulatory review.

Specific XAI techniques include SHAP (SHapley Additive exPlanations) values, which quantify the contribution of each input feature to a model prediction, and attention mechanisms that highlight regions of input data most relevant to model outputs [38]. The selection of appropriate XAI techniques depends on the model architecture and the information needs of users and regulators.

The EMA's reflection paper on the use of AI in the medicinal product lifecycle, finalized in September 2024,

emphasizes transparency and explainability requirements [39]. The paper notes that AI systems affecting patient safety or regulatory decisions require comprehensive documentation of development, validation, and ongoing monitoring, including approaches to ensure interpretability of model outputs.

4.4. Alignment with ICH Quality Guidelines

The ICH Q8, Q9, and Q10 guidelines establish an integrated framework for pharmaceutical development, quality risk management, and pharmaceutical quality systems that aligns well with AI-enabled cleaning validation approaches [40].

ICH Q9 (Quality Risk Management) provides principles and tools for identifying, assessing, and controlling quality risks throughout the product lifecycle [41]. AI predictive models can enhance risk assessment by quantifying the probability and magnitude of cleaning failures under various conditions. Risk-based sampling strategies justified by AI analysis implement the Q9 principle of focusing resources on highest-risk areas.

ICH Q10 (Pharmaceutical Quality System) emphasizes continual improvement of processes and systems throughout the product lifecycle [42]. AI monitoring of cleaning process performance, identification of trends, and optimization recommendations directly support this continual improvement mandate. The pharmaceutical quality system elements described in Q10, including process performance monitoring, CAPA systems, and change management, provide the governance framework within which AI tools operate.

The ICH Q12 guideline on lifecycle management further emphasizes the value of enhanced process understanding and the use of science and risk-based approaches for managing post-approval changes [43]. AI-generated process knowledge, captured in predictive models and validated through ongoing monitoring, provides the foundation for more flexible, science-based change management.

5. Discussion: Challenges and Barriers to Implementation

5.1. Technical Challenges

The implementation of AI in cleaning validation faces substantial technical challenges that must be addressed for successful deployment.

5.1.1. Data Quality and Availability

Machine learning models require substantial quantities of high-quality training data. For cleaning validation applications, this data must encompass the range of products, equipment, cleaning procedures, and outcomes relevant to the facility. Many organizations lack comprehensive historical databases, with cleaning data fragmented across paper records, disparate electronic systems, and institutional memory [44].

"Dirty data," containing errors, inconsistencies, or missing values, can compromise model performance. Data preprocessing to address quality issues may require significant effort, and some historical data may be unsuitable for model development. The establishment of robust data collection systems should precede or accompany AI implementation efforts.

5.1.2. Sensor Integration and Calibration

PAT-based monitoring requires appropriate sensors integrated into cleaning systems. Retrofitting existing CIP systems with spectroscopic probes, cameras, or other sensors may present engineering challenges. Sensor selection must consider the harsh environment of cleaning operations, including exposure to cleaning agents, elevated temperatures, and high-pressure sprays.

Ongoing sensor calibration and maintenance ensure continued measurement accuracy. Spectroscopic instruments require reference standards appropriate to the measurement range and application. Camera systems require consistent lighting and periodic verification of imaging performance. The operational burden of sensor maintenance must be considered when evaluating AI implementation costs and benefits.

5.1.3. Model Development and Validation

The development of AI models for cleaning validation applications requires specialized expertise spanning pharmaceutical science, data science, and software engineering. Many pharmaceutical organizations lack internal capabilities in AI development, necessitating partnerships with technology vendors or academic institutions.

Model validation must demonstrate fitness for purpose in the specific context of use. This validation extends beyond traditional software validation to address the unique characteristics of AI systems, including performance on data not used in training, robustness to input variations, and behavior in edge cases. Validation approaches are evolving as regulatory expectations crystallize, creating uncertainty for early adopters.

5.2. Organizational Barriers

Technical solutions alone are insufficient for successful AI implementation. Organizational factors including culture, skills, and change management present equally significant challenges.

5.2.1. The "Status Quo" Mindset

Pharmaceutical manufacturing is inherently conservative, with strong cultural emphasis on following validated procedures and avoiding changes that might introduce risk. This conservatism, while appropriate given patient safety implications, can create resistance to transformative technologies perceived as unproven or risky [45].

The established three-batch validation paradigm, despite its limitations, is familiar, well-understood by regulators, and defensible. Transitioning to continuous verification approaches requires philosophical shifts in how validation is conceptualized and documented. Champions at leadership levels must articulate the vision for AI-enabled validation and create organizational permission to pursue transformation.

5.2.2. Skills Gaps

AI implementation requires skills not traditionally found in pharmaceutical quality and manufacturing organizations. Data science, machine learning engineering, and software development expertise must be acquired through hiring, training, or external partnerships [46]. Quality assurance personnel must develop sufficient

understanding of AI concepts to evaluate model validity and interpret outputs.

Cross-functional collaboration becomes essential, breaking down traditional silos between IT, quality, manufacturing, and engineering functions. The organizational structures and processes that enabled success in traditional paradigms may require modification to support the integrated, data-driven approaches that AI enables.

5.2.3. Change Management

The introduction of AI systems changes workflows, responsibilities, and decision-making processes. Cleaning operators accustomed to following prescriptive procedures may need to engage with AI recommendations and exercise judgment about when to override model predictions. Quality reviewers must learn to evaluate AI outputs alongside traditional analytical results.

Effective change management requires clear communication about the purpose and benefits of AI implementation, training programs tailored to different user roles, and support systems for addressing questions and concerns. Pilot implementations in limited scope applications can build experience and confidence before broader deployment.

5.3. Ethical and Safety Considerations

The deployment of AI in pharmaceutical manufacturing raises ethical considerations beyond regulatory compliance that merit explicit attention.

5.3.1. Over-Reliance on Automated Decisions

AI systems, particularly those that demonstrate high performance during development and validation, may engender excessive trust that reduces appropriate human oversight. Operators may accept AI recommendations without critical evaluation, potentially missing situations where the AI model performs poorly [47].

The human-in-the-loop principle, emphasized in regulatory guidance, requires that humans retain meaningful decision-making authority. AI systems should be designed to support rather than replace human judgment, with outputs presented in ways that encourage review and enable override when appropriate.

5.3.2. Accountability and Responsibility

When AI systems contribute to decisions affecting product quality, questions of accountability arise. If a cleaning cycle released based partly on AI analysis is subsequently found inadequate, responsibility must be clearly assigned. Regulatory frameworks hold manufacturers accountable regardless of the technologies employed, but internal governance must ensure clear understanding of who is responsible for AI system validation, ongoing monitoring, and ultimate product quality decisions [48].

Documentation requirements for AI-assisted decisions must enable reconstruction of the basis for decisions during regulatory inspections or quality investigations. This traceability requirement extends the traditional documentation expectations to encompass AI model outputs, confidence measures, and any human review or override actions.

5.3.3. Bias and Fairness Considerations

AI models can perpetuate or amplify biases present in training data. For cleaning validation applications, biases might include models that perform well for products well-represented in training data but poorly for newer products, or models developed primarily with data from one facility that generalize poorly to others.

Careful attention to training data composition, validation across relevant subgroups, and ongoing performance monitoring helps identify and address bias concerns. The diversity of products, equipment, and conditions represented in training data should reflect the intended scope of model application.

6. Future Directions and Sustainability Considerations

6.1. Emerging Technologies and Integration Pathways

The trajectory of AI development suggests continued advancement in capabilities relevant to cleaning validation. Large Language Models (LLMs) offer potential for more sophisticated document analysis and generation. Generative AI might assist with protocol development or report writing. Edge computing enables AI inference at the point of measurement, reducing latency and data transmission requirements [49].

The integration of AI cleaning validation systems with broader facility digitalization initiatives, including Manufacturing Execution Systems (MES), Enterprise Resource Planning (ERP), and Laboratory Information Management Systems (LIMS), creates opportunities for enhanced workflow optimization and decision support [50]. Data generated by cleaning processes can inform broader production scheduling, quality trending, and continuous improvement initiatives.

Blockchain technology offers potential for immutable audit trails that could further strengthen data integrity for AI-enabled systems. Distributed ledger approaches might also facilitate data sharing for model development across organizations while protecting proprietary information.

6.2. Sustainability and Environmental Benefits

AI-optimized cleaning processes can contribute significantly to pharmaceutical manufacturing sustainability objectives. The pharmaceutical industry consumes substantial quantities of water and energy for cleaning operations, and generates wastewater requiring treatment before discharge. Optimization of cleaning cycle durations, rinse volumes, and cleaning agent concentrations directly reduces resource consumption and environmental impact [51].

Predictive capabilities can enable "just-right" cleaning approaches that apply appropriate rigor based on actual contamination risk rather than worst-case assumptions. Products with low residue potential or high water solubility might be cleaned with shorter cycles and reduced water volumes, while more challenging products receive the intensive cleaning they require.

The quantification of sustainability benefits provides additional justification for AI investment beyond operational efficiency. Environmental, Social, and Governance (ESG) commitments increasingly influence pharmaceutical industry decisions, and documented reductions in water and energy consumption through AI optimization align with these priorities.

6.3. Regulatory Evolution and Global Harmonization

Regulatory frameworks for AI in pharmaceutical manufacturing continue to evolve. The FDA's commitment to developing comprehensive guidance on AI in drug manufacturing, signaled through discussion papers and pilot programs, suggests that more specific regulatory expectations will emerge [52]. The EMA's reflection paper provides a foundation for European approaches that emphasize risk-based assessment and lifecycle management.

International harmonization through ICH working groups may eventually produce globally applicable guidance on AI in GMP environments. Organizations implementing AI today must navigate regulatory uncertainty while building systems flexible enough to adapt to crystallizing requirements. Engagement with regulators through available channels, including pre-submission meetings, pilot programs, and industry forums, helps inform both implementation decisions and regulatory development.

7. Conclusion

The integration of artificial intelligence into pharmaceutical cleaning validation represents a paradigm shift from retrospective compliance verification to prospective quality assurance. This transformation aligns with broader regulatory evolution emphasizing Quality by Design, lifecycle management, and risk-based approaches as articulated in ICH Q8, Q9, and Q10 guidelines.

Machine learning algorithms enable predictive modeling of cleaning outcomes, allowing optimization of cleaning parameters and early identification of emerging issues. Computer vision systems provide automated visual inspection capabilities that exceed human consistency while operating at production line speeds. PAT integration with AI-enhanced spectroscopic analysis enables real-time monitoring of cleaning processes, providing continuous assurance rather than endpoint verification. Natural language processing supports documentation review and regulatory intelligence functions.

The regulatory landscape, while still evolving, increasingly accommodates AI technologies within established compliance frameworks. The FDA's January 2025 draft guidance on AI for regulatory decision-making and the EMA's 2024 reflection paper on AI in the medicinal product lifecycle provide foundational guidance emphasizing risk-based credibility assessment, transparency, and human oversight. Data integrity requirements under ALCOA+ principles can be strengthened through properly designed AI systems with robust audit trails and access controls.

Implementation challenges span technical, organizational, and ethical domains. Data quality and availability, sensor integration, and model validation present technical hurdles. Organizational culture, skills gaps, and change management require attention alongside technology deployment. Ethical considerations including appropriate human oversight, accountability, and bias prevention must inform system design and governance.

The benefits of successful AI implementation extend beyond operational efficiency to encompass enhanced data integrity, improved process understanding, and contributions to sustainability objectives. Organizations that develop AI capabilities for cleaning validation position themselves for competitive advantage in an industry increasingly shaped by digital transformation.

As the pharmaceutical industry continues its evolution toward Pharma 4.0, AI-enabled cleaning validation exemplifies the broader transformation of manufacturing from batch-oriented, manually intensive processes to continuous, data-driven operations. The journey requires investment, expertise, and organizational commitment, but the destination, manufacturing processes that are more efficient, more reliable, and better understood, justifies the effort for organizations prepared to embrace the opportunity.

References

1. U.S. Food and Drug Administration. Guidance for industry: Process validation: general principles and practices [Internet]. Silver Spring (MD): FDA; 2011 [cited 2026 Apr 3]. Available from: https://www.fda.gov/media/71021/download
2. European Medicines Agency. Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012) [Internet]. London: EMA; 2014 [cited 2026 Apr 3]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-setting-health-based-exposure-limits-use-risk-identification-manufacture-different-medicinal-products-shared-facilities_en.pdf
3. LeBlanc DA. Establishing scientifically justified acceptance criteria for cleaning validation of finished drug products. Pharm Technol. 2000;24(10):136–148.
4. Walsh A, Ovais M, Altmann T, Sargent EV. Cleaning validation for the 21st century: Acceptance limits for cleaning agents. Pharm Eng. 2013;33(6):12–24.
5. Forsyth RJ. Best practices for cleaning validation swab recovery studies. Pharm Technol. 2016;40(9):40–53.
6. Hall WE. Validation and verification of cleaning processes. In: Agalloco J, Carleton F, editors. Pharmaceutical process validation. 3rd ed. Boca Raton (FL): CRC Press; 2003. p. 508–549. Available from: https://doi.org/10.1201/9780203912119
7. U.S. Food and Drug Administration. Data integrity and compliance with drug CGMP: Questions and answers [Internet]. Silver Spring (MD): FDA; 2018 [cited 2026 Apr 3]. Available from: https://www.fda.gov/media/119267/download
8. International Society for Pharmaceutical Engineering. ISPE baseline guide: Risk-based manufacture of pharmaceutical products (Risk-MaPP). 2nd ed. Tampa (FL): ISPE; 2017.
9. World Health Organization. WHO technical report series, no. 996, annex 5: Guidance on good data and record management practices. Geneva: WHO; 2016.
10. U.S. Food and Drug Administration. Guidance for industry: PAT—A framework for innovative pharmaceutical development, manufacturing, and quality assurance [Internet]. Silver Spring (MD): FDA; 2004 [cited 2026 Apr 3]. Available from: https://www.fda.gov/media/71012/download
11. International Council for Harmonisation. ICH Q10: Pharmaceutical quality system [Internet]. Geneva: ICH; 2008 [cited 2026 Apr 3]. Available from:

https://database.ich.org/sites/default/files/Q10%20Guideline.pdf
12. Reinhardt IC, Oliveira JC, Ring DT. Current perspectives on the development of Industry 4.0 in the pharmaceutical sector. J Ind Inf Integr. 2020;18:100131.
13. Jordan MI, Mitchell TM. Machine learning: Trends, perspectives, and prospects. Science. 2015;349(6245):255–260.
14. Breiman L. Random forests. Mach Learn. 2001;45(1):5–32.
15. Nuñez JR, Grau RI, Rizzo MM. Artificial intelligence and internet of things integration in pharmaceutical manufacturing: A smart synergy. Pharmaceutics. 2024;16(3):367.
16. Cognex Corporation. How AI and machine vision improve pharmaceutical product quality and yield [Internet]. 2023 [cited 2026 Apr 3]. Available from: https://www.cognex.com/blogs/machine-vision/how-ai-and-machine-vision-improve-pharmaceutical-product-quality-and-yield
17. LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521(7553):436–444.
18. Redmon J, Divvala S, Girshick R, Farhadi A. You only look once: Unified, real-time object detection. In: Proc IEEE Conf Comput Vis Pattern Recognit. 2016. p. 779–788.
19. Gowen AA, O'Donnell CP, Cullen PJ, Downey G, Frias JM. Hyperspectral imaging—an emerging process analytical tool for food quality and safety control. Trends Food Sci Technol. 2007;18(12):590–598.
20. U.S. Food and Drug Administration. Guidance for industry: PAT—A framework for innovative pharmaceutical development, manufacturing, and quality assurance. Silver Spring (MD): FDA; 2004.
21. Risoluti R, Materazzi S, Gregori A, Ripani L. Portable NIR spectroscopy: The route to green analytical chemistry. Front Chem. 2023;11:1214825.
22. Marques C, Leiria M, Cabral JMS. Application of process analytical technology (PAT) in real-time monitoring of pharmaceutical cleaning process. Process Saf Environ Prot. 2023;178:45–56.
23. Bjerrum EJ, Glahder M, Skov T. Data augmentation of spectral data for convolutional neural network (CNN) based deep chemometrics. arXiv [Preprint]. 2017.
24. Castanedo F. A review of data fusion techniques. Sci World J. 2013;2013:704504.
25. Kreimeyer K, Foster M, Pandey A, Arber N, Mober W, Sparks T, *et al*. Natural language processing systems for capturing and standardizing unstructured clinical information: A systematic review. J Biomed Inform. 2017;73:14–29.
26. Pharma Tips. Cleaning cycle time reduction strategies in pharmaceutical manufacturing [Internet]. 2025 [cited 2026 Apr 3]. Available from: https://www.pharma.tips/cleaning-cycle-time-reduction-strategies-in-pharmaceutical-manufacturing/
27. ASTM International. ASTM E3106-17: Standard guide for science-based and risk-based cleaning process development and validation. West Conshohocken (PA): ASTM; 2017.
28. Montgomery DC. Introduction to statistical quality control. 8th ed. Hoboken (NJ): Wiley; 2019.
29. Forsyth RJ, Hartman J, Van Nostrand V. Risk-management assessment of visible-residue limits in cleaning validation. Pharm Technol. 2006;30(9):101–114.
30. Palabiyik I, Olunloyo B. CFD modelling of cleaning in pharmaceutical manufacturing equipment. AIChE J. 2021;67(5):e17160.
31. U.S. Food and Drug Administration. Data integrity and compliance with drug CGMP: Questions and answers. Silver Spring (MD): FDA; 2018.
32. Pharmaceutical Inspection Co-operation Scheme. PIC/S guidance: Good practices for data management and integrity in regulated GMP/GDP environments (PI 041-1). Geneva: PIC/S; 2021.
33. U.S. Food and Drug Administration. Guidance for industry: Part 11, electronic records; electronic signatures—scope and application [Internet]. Silver Spring (MD): FDA; 2003 [cited 2026 Apr 3]. Available from: https://www.fda.gov/media/75414/download
34. Rudin C. Stop explaining black box machine learning models for high-stakes decisions and use interpretable models instead. Nat Mach Intell. 2019;1(5):206–215.
35. U.S. Food and Drug Administration. Draft guidance for industry: Considerations for the use of artificial intelligence to support regulatory decision-making for drug and biological products [Internet]. Silver Spring (MD): FDA; 2025 [cited 2026 Apr 3]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological
36. Sommer J, Fanelli C, von Mühlenen E, Gandolfo M, Lipiz J. Regulatory perspectives for AI/ML implementation in pharmaceutical GMP environments. Pharmaceuticals. 2025;18(6):752.
37. Barredo Arrieta A, Díaz-Rodríguez N, Del Ser J, Bennetot A, Tabik S, Barbado A, *et al*. Explainable artificial intelligence (XAI): Concepts, taxonomies, opportunities and challenges. Inf Fusion. 2020;58:82–115.
38. Lundberg SM, Lee SI. A unified approach to interpreting model predictions. In: Adv Neural Inf Process Syst. 2017;30:4765–4774.
39. European Medicines Agency. Reflection paper on the use of artificial intelligence (AI) in the medicinal product lifecycle (EMA/CHMP/CVMP/83833/2023) [Internet]. London: EMA; 2024 [cited 2026 Apr 3]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle_en.pdf
40. International Council for Harmonisation. ICH Q8(R2): Pharmaceutical development [Internet]. Geneva: ICH; 2009 [cited 2026 Apr 3]. Available from: https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf
41. International Council for Harmonisation. ICH Q9(R1): Quality risk management [Internet]. Geneva: ICH; 2023 [cited 2026 Apr 3]. Available from: https://database.ich.org/sites/default/files/ICH_Q9%2

8R1%29_Guideline_Step4_2023_0126_0.pdf
42. International Council for Harmonisation. ICH Q10: Pharmaceutical quality system. Geneva: ICH; 2008.
43. International Council for Harmonisation. ICH Q12: Technical and regulatory considerations for pharmaceutical product lifecycle management [Internet]. Geneva: ICH; 2019 [cited 2026 Apr 3]. Available from: https://database.ich.org/sites/default/files/Q12_Guideline_Step4_2019_1119.pdf
44. Manzano T, Sánchez M. Machine learning and data quality challenges in pharmaceutical manufacturing. J Pharm Innov. 2023;18(2):789–803.
45. Berman JJ. Principles of big data: Preparing, sharing, and analyzing complex information. Waltham (MA): Morgan Kaufmann; 2013.
46. Liu Q, Huang R, Hsieh J, Zhu H, Tiwari M, Liu G, *et al*. Landscape analysis of the application of artificial intelligence and machine learning in regulatory submissions for drug development from 2016 to 2021. Clin Pharmacol Ther. 2023;113(4):771–774.
47. Parasuraman R, Riley V. Humans and automation: Use, misuse, disuse, abuse. Hum Factors. 1997;39(2):230–253.
48. Nair S. Explainable AI in GxP validation: Balancing automation, traceability, and regulatory trust in the pharmaceutical industry. Clin Med Health Res J. 2025;5(3):1430–1442.
49. Shi W, Cao J, Zhang Q, Li Y, Xu L. Edge computing: Vision and challenges. IEEE Internet Things J. 2016;3(5):637–646.
50. Viso.ai. Computer vision in pharmaceutical applications [Internet]. 2024 [cited 2026 Apr 3]. Available from: https://viso.ai/applications/computer-vision-in-the-pharmaceutical-industry/
51. Kneat. Cleaning validation: Best practices for pharmaceutical manufacturing [Internet]. 2025 [cited 2026 Apr 3]. Available from: https://kneat.com/article/cleaning-validation/
52. U.S. Food and Drug Administration. Artificial intelligence in drug manufacturing: Discussion paper [Internet]. Silver Spring (MD): FDA; 2023 [cited 2026 Apr 3]. Available from: https://www.fda.gov/media/165743/download

How to Cite This Article
Patel B, Pacha N, Patel J. Leveraging artificial intelligence for real-time cleaning validation: a risk-based lifecycle approach to Pharma 4.0. Int J Multidiscip Res Growth Eval. 2026 Mar-Apr;7(2):474–484.
doi:10.54660/IJMRGE.2026.7.2.474-484.